Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Panitumumab « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Panitumumab

Posted on June 26, 2008 by crimsoncanary

Data presented today at the 10th World Congress on Gastrointestinal Cancer shows that preemptive treatment reduced the incidence rate of grade two and higher skin toxicities by over 50 percent without additional side effect.

Filed under: Kinase receptor | Tagged: ABX-EGF, Amgen, EGFR, Monoclonal, panitumumab, Takeda, Vectibix

« Eberhard-Karls-University publish series of p38 inhibitors Exelixis and GlaxoSmithKline Conclude Six-Year Discovery and Development Collaboration »